Skip to content
Parakho

Novelix Pharmaceuticals Ltd

BSE 536565

Q1 FY27, unaudited

Revenue
₹36.91 Cr
Profit after tax
₹1.18 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with BSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations36.91+65.15%132.31
Other income0.00—0.03
Total income36.92+65.16%132.34
Employee benefit expense0.20+19.44%0.72
Finance costs0.12—0.00
Depreciation & amortisation0.07+536.36%0.10
Total expenses35.80+61.39%128.93
Profit before tax1.12+558.38%3.40
Tax expense-0.06−201.92%0.85
Profit after tax1.18+1,001.78%2.56
Total comprehensive income1.18+1,001.78%2.56
Earnings per share
Earnings per share, basic₹0.49₹1.21
Earnings per share, diluted₹0.49₹1.75

Q1 FY27 — unaudited, from the company’s filing with BSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with BSE. Source

FY26 — from the company’s filing with BSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Novelix Pharmaceuticals Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 65 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Healthcare Research, Analytics & Technology

Classification as published by BSE.

Companies also in Healthcare Research, Analytics & Technology, in alphabetical order

All 11 companies in Healthcare Research, Analytics & Technology

Page generated from filings held to 06 Oct 2026.